The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed, and funded by an Alkermes company.
Showing 10 of 103 results
Sort by date:
Descending
Apr 2020
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Mar 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Feb 2020
Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism
Addiction
AUTHOR(S)
Jan 2020
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
Clinical Drug Investigation
AUTHOR(S)
Jan 2020
Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
CPT: Pharmacometrics & Systems Pharmacology
AUTHOR(S)
Aug 2019
Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
Neuropsychiatric Disease and Treatment
AUTHOR(S)
Aug 2019
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
CNS Spectrums
AUTHOR(S)
Jul 2019
Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period
CNS Spectrums
AUTHOR(S)
Jul 2019
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
Drug Design, Development and Therapy
AUTHOR(S)
Jun 2019
Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
Therapeutic Advances in Psychopharmacology
AUTHOR(S)
